Max Robotics — Global Service Robot Directory + US Certification

About

Guido Kroemer is a pioneering cell biologist whose research lies at the intersection of immunology, autophagy, and cancer therapy. His major contributions have reshaped our understanding of how cell death mechanisms can be harnessed for therapeutic benefit. Kroemer is best known for his work on immunogenic cell death (ICD), demonstrating that certain anticancer agents, such as the oncolytic peptide LTX-315, can trigger a form of necrosis that stimulates a potent T lymphocyte-mediated immune response—a concept with over 129 citations in his seminal 2016 paper. He has also advanced the field of autophagy, showing that pharmacological enhancement of this process can amplify the effects of cancer drugs via immune-dependent mechanisms, as evidenced by his highly cited 2021 study (77 citations). Beyond these discoveries, Kroemer developed high-throughput methodologies for quantifying cellular viability and autophagy, including automated microscopy and flow cytometry techniques that have become standard tools in the lab. His work has profound implications for aging and cancer, earning him recognition as one of the most influential researchers in cell death and autophagy.